Comparing two blood thinners for kidney dialysis in sepsis
Treatments studied
Part of Infections, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study compares two ways to prevent blood clots during kidney dialysis in people with sepsis-related kidney failure. The goal is to see which method is safer and works better to keep the dialysis filter working properly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between the ages of 18 and 90.
- You must have sepsis and have developed acute kidney injury within the past 7 days.
- Your kidney injury must be severe enough that you need dialysis (a machine to filter your blood) for more than 2 days.
- You cannot be taking blood thinners for a blood clot or have a condition that makes blood thinners unsafe.
- You must not have a history of chronic kidney disease that requires regular dialysis, or other kidney diseases like glomerulonephritis.
- You cannot be pregnant, planning pregnancy, or breastfeeding, and you must not have HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two blood-thinning drugs (nafamostat and heparin) that are given during dialysis for kidney failure caused by sepsis. The goal is to see which drug is safer and helps keep the dialysis filter working better.
This study compares two blood-thinning medications used during continuous dialysis for acute kidney injury: one uses citrate (a chemical that prevents clotting) and the other uses heparin (a standard blood thinner). By looking at how well these treatments work, the study aims to find the safest and most effective way to keep the dialysis filter working.
This study tests whether a specific blood-thinning method using citrate works safely and effectively in critically ill patients whose kidneys have suddenly stopped working and need a special filtering machine. Researchers want to confirm that this approach prevents dangerous blood clots while keeping patients safe.
This study tests a special blood-filtering treatment for patients in the intensive care unit (ICU) with acute kidney injury. It uses a medicine called citrate to prevent blood clotting during dialysis, which may be safer for patients whose liver cannot process citrate normally.
This trial is testing different doses of a blood thinner called nafamostat in patients who are in the ICU and need continuous kidney dialysis (CRRT). The goal is to find which dose works best to prevent clots in the dialysis machine without causing bleeding problems.
This trial tests whether a special type of dialysis filter (oXiris) helps reduce blood clotting problems in patients with septic shock and kidney failure. It may offer a better option for those needing kidney support in the ICU.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.